Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
161,353
archived clinical trials in
Cancer

A Study of Rucaparib as Switch Maintenance Following Platinum-Based Chemotherapy in Patients With Platinum-Sensitive, High-Grade Serous or Endometrioid Epithelial Ovarian, Primary Peritoneal or Fallopian Tube Cancer
Phase 3 Study of Rucaparib as Switch Maintenance After Platinum in Relapsed High Grade Serous and Endometrioid Ovarian Cancer (ARIEL3)
Status: Enrolling
Updated:  12/31/1969
Karmanos Cancer Institute/Wayne State University
mi
from
Detroit, MI
A Study of Rucaparib as Switch Maintenance Following Platinum-Based Chemotherapy in Patients With Platinum-Sensitive, High-Grade Serous or Endometrioid Epithelial Ovarian, Primary Peritoneal or Fallopian Tube Cancer
Phase 3 Study of Rucaparib as Switch Maintenance After Platinum in Relapsed High Grade Serous and Endometrioid Ovarian Cancer (ARIEL3)
Status: Enrolling
Updated: 12/31/1969
Karmanos Cancer Institute/Wayne State University
mi
from
Detroit, MI
Click here to add this to my saved trials
A Study of Rucaparib as Switch Maintenance Following Platinum-Based Chemotherapy in Patients With Platinum-Sensitive, High-Grade Serous or Endometrioid Epithelial Ovarian, Primary Peritoneal or Fallopian Tube Cancer
Phase 3 Study of Rucaparib as Switch Maintenance After Platinum in Relapsed High Grade Serous and Endometrioid Ovarian Cancer (ARIEL3)
Status: Enrolling
Updated:  12/31/1969
Memorial Sloan Kettering Cancer Center
mi
from
New York, NY
A Study of Rucaparib as Switch Maintenance Following Platinum-Based Chemotherapy in Patients With Platinum-Sensitive, High-Grade Serous or Endometrioid Epithelial Ovarian, Primary Peritoneal or Fallopian Tube Cancer
Phase 3 Study of Rucaparib as Switch Maintenance After Platinum in Relapsed High Grade Serous and Endometrioid Ovarian Cancer (ARIEL3)
Status: Enrolling
Updated: 12/31/1969
Memorial Sloan Kettering Cancer Center
mi
from
New York, NY
Click here to add this to my saved trials
A Study of Rucaparib as Switch Maintenance Following Platinum-Based Chemotherapy in Patients With Platinum-Sensitive, High-Grade Serous or Endometrioid Epithelial Ovarian, Primary Peritoneal or Fallopian Tube Cancer
Phase 3 Study of Rucaparib as Switch Maintenance After Platinum in Relapsed High Grade Serous and Endometrioid Ovarian Cancer (ARIEL3)
Status: Enrolling
Updated:  12/31/1969
Hope Women's Cancer Centers
mi
from
Asheville, NC
A Study of Rucaparib as Switch Maintenance Following Platinum-Based Chemotherapy in Patients With Platinum-Sensitive, High-Grade Serous or Endometrioid Epithelial Ovarian, Primary Peritoneal or Fallopian Tube Cancer
Phase 3 Study of Rucaparib as Switch Maintenance After Platinum in Relapsed High Grade Serous and Endometrioid Ovarian Cancer (ARIEL3)
Status: Enrolling
Updated: 12/31/1969
Hope Women's Cancer Centers
mi
from
Asheville, NC
Click here to add this to my saved trials
A Study of Rucaparib as Switch Maintenance Following Platinum-Based Chemotherapy in Patients With Platinum-Sensitive, High-Grade Serous or Endometrioid Epithelial Ovarian, Primary Peritoneal or Fallopian Tube Cancer
Phase 3 Study of Rucaparib as Switch Maintenance After Platinum in Relapsed High Grade Serous and Endometrioid Ovarian Cancer (ARIEL3)
Status: Enrolling
Updated:  12/31/1969
The Ohio State University, Wexner Medical Center
mi
from
Columbus, OH
A Study of Rucaparib as Switch Maintenance Following Platinum-Based Chemotherapy in Patients With Platinum-Sensitive, High-Grade Serous or Endometrioid Epithelial Ovarian, Primary Peritoneal or Fallopian Tube Cancer
Phase 3 Study of Rucaparib as Switch Maintenance After Platinum in Relapsed High Grade Serous and Endometrioid Ovarian Cancer (ARIEL3)
Status: Enrolling
Updated: 12/31/1969
The Ohio State University, Wexner Medical Center
mi
from
Columbus, OH
Click here to add this to my saved trials
A Study of Rucaparib as Switch Maintenance Following Platinum-Based Chemotherapy in Patients With Platinum-Sensitive, High-Grade Serous or Endometrioid Epithelial Ovarian, Primary Peritoneal or Fallopian Tube Cancer
Phase 3 Study of Rucaparib as Switch Maintenance After Platinum in Relapsed High Grade Serous and Endometrioid Ovarian Cancer (ARIEL3)
Status: Enrolling
Updated:  12/31/1969
Univ of Pennsylvania
mi
from
Philadelphia, PA
A Study of Rucaparib as Switch Maintenance Following Platinum-Based Chemotherapy in Patients With Platinum-Sensitive, High-Grade Serous or Endometrioid Epithelial Ovarian, Primary Peritoneal or Fallopian Tube Cancer
Phase 3 Study of Rucaparib as Switch Maintenance After Platinum in Relapsed High Grade Serous and Endometrioid Ovarian Cancer (ARIEL3)
Status: Enrolling
Updated: 12/31/1969
Univ of Pennsylvania
mi
from
Philadelphia, PA
Click here to add this to my saved trials
A Study of Rucaparib as Switch Maintenance Following Platinum-Based Chemotherapy in Patients With Platinum-Sensitive, High-Grade Serous or Endometrioid Epithelial Ovarian, Primary Peritoneal or Fallopian Tube Cancer
Phase 3 Study of Rucaparib as Switch Maintenance After Platinum in Relapsed High Grade Serous and Endometrioid Ovarian Cancer (ARIEL3)
Status: Enrolling
Updated:  12/31/1969
University of Texas M.D. Anderson Cancer Center
mi
from
Houston, TX
A Study of Rucaparib as Switch Maintenance Following Platinum-Based Chemotherapy in Patients With Platinum-Sensitive, High-Grade Serous or Endometrioid Epithelial Ovarian, Primary Peritoneal or Fallopian Tube Cancer
Phase 3 Study of Rucaparib as Switch Maintenance After Platinum in Relapsed High Grade Serous and Endometrioid Ovarian Cancer (ARIEL3)
Status: Enrolling
Updated: 12/31/1969
University of Texas M.D. Anderson Cancer Center
mi
from
Houston, TX
Click here to add this to my saved trials
A Study of Rucaparib as Switch Maintenance Following Platinum-Based Chemotherapy in Patients With Platinum-Sensitive, High-Grade Serous or Endometrioid Epithelial Ovarian, Primary Peritoneal or Fallopian Tube Cancer
Phase 3 Study of Rucaparib as Switch Maintenance After Platinum in Relapsed High Grade Serous and Endometrioid Ovarian Cancer (ARIEL3)
Status: Enrolling
Updated:  12/31/1969
University of Washington, Seattle
mi
from
Seattle, WA
A Study of Rucaparib as Switch Maintenance Following Platinum-Based Chemotherapy in Patients With Platinum-Sensitive, High-Grade Serous or Endometrioid Epithelial Ovarian, Primary Peritoneal or Fallopian Tube Cancer
Phase 3 Study of Rucaparib as Switch Maintenance After Platinum in Relapsed High Grade Serous and Endometrioid Ovarian Cancer (ARIEL3)
Status: Enrolling
Updated: 12/31/1969
University of Washington, Seattle
mi
from
Seattle, WA
Click here to add this to my saved trials
A Study of Rucaparib as Switch Maintenance Following Platinum-Based Chemotherapy in Patients With Platinum-Sensitive, High-Grade Serous or Endometrioid Epithelial Ovarian, Primary Peritoneal or Fallopian Tube Cancer
Phase 3 Study of Rucaparib as Switch Maintenance After Platinum in Relapsed High Grade Serous and Endometrioid Ovarian Cancer (ARIEL3)
Status: Enrolling
Updated:  12/31/1969
Prince of Wales Hospital
mi
from
Sydney,
A Study of Rucaparib as Switch Maintenance Following Platinum-Based Chemotherapy in Patients With Platinum-Sensitive, High-Grade Serous or Endometrioid Epithelial Ovarian, Primary Peritoneal or Fallopian Tube Cancer
Phase 3 Study of Rucaparib as Switch Maintenance After Platinum in Relapsed High Grade Serous and Endometrioid Ovarian Cancer (ARIEL3)
Status: Enrolling
Updated: 12/31/1969
Prince of Wales Hospital
mi
from
Sydney,
Click here to add this to my saved trials
A Study of Rucaparib as Switch Maintenance Following Platinum-Based Chemotherapy in Patients With Platinum-Sensitive, High-Grade Serous or Endometrioid Epithelial Ovarian, Primary Peritoneal or Fallopian Tube Cancer
Phase 3 Study of Rucaparib as Switch Maintenance After Platinum in Relapsed High Grade Serous and Endometrioid Ovarian Cancer (ARIEL3)
Status: Enrolling
Updated:  12/31/1969
Beth Israel Deaconess Medical Center
mi
from
Boston, MA
A Study of Rucaparib as Switch Maintenance Following Platinum-Based Chemotherapy in Patients With Platinum-Sensitive, High-Grade Serous or Endometrioid Epithelial Ovarian, Primary Peritoneal or Fallopian Tube Cancer
Phase 3 Study of Rucaparib as Switch Maintenance After Platinum in Relapsed High Grade Serous and Endometrioid Ovarian Cancer (ARIEL3)
Status: Enrolling
Updated: 12/31/1969
Beth Israel Deaconess Medical Center
mi
from
Boston, MA
Click here to add this to my saved trials
A Study of Rucaparib as Switch Maintenance Following Platinum-Based Chemotherapy in Patients With Platinum-Sensitive, High-Grade Serous or Endometrioid Epithelial Ovarian, Primary Peritoneal or Fallopian Tube Cancer
Phase 3 Study of Rucaparib as Switch Maintenance After Platinum in Relapsed High Grade Serous and Endometrioid Ovarian Cancer (ARIEL3)
Status: Enrolling
Updated:  12/31/1969
Washington University School of Medicine - Division of Gynaecological Oncology
mi
from
Saint Louis, MO
A Study of Rucaparib as Switch Maintenance Following Platinum-Based Chemotherapy in Patients With Platinum-Sensitive, High-Grade Serous or Endometrioid Epithelial Ovarian, Primary Peritoneal or Fallopian Tube Cancer
Phase 3 Study of Rucaparib as Switch Maintenance After Platinum in Relapsed High Grade Serous and Endometrioid Ovarian Cancer (ARIEL3)
Status: Enrolling
Updated: 12/31/1969
Washington University School of Medicine - Division of Gynaecological Oncology
mi
from
Saint Louis, MO
Click here to add this to my saved trials
A Study of Rucaparib as Switch Maintenance Following Platinum-Based Chemotherapy in Patients With Platinum-Sensitive, High-Grade Serous or Endometrioid Epithelial Ovarian, Primary Peritoneal or Fallopian Tube Cancer
Phase 3 Study of Rucaparib as Switch Maintenance After Platinum in Relapsed High Grade Serous and Endometrioid Ovarian Cancer (ARIEL3)
Status: Enrolling
Updated:  12/31/1969
UC Davis Comprehensive Cancer Center
mi
from
Sacramento, CA
A Study of Rucaparib as Switch Maintenance Following Platinum-Based Chemotherapy in Patients With Platinum-Sensitive, High-Grade Serous or Endometrioid Epithelial Ovarian, Primary Peritoneal or Fallopian Tube Cancer
Phase 3 Study of Rucaparib as Switch Maintenance After Platinum in Relapsed High Grade Serous and Endometrioid Ovarian Cancer (ARIEL3)
Status: Enrolling
Updated: 12/31/1969
UC Davis Comprehensive Cancer Center
mi
from
Sacramento, CA
Click here to add this to my saved trials
A Study of Rucaparib as Switch Maintenance Following Platinum-Based Chemotherapy in Patients With Platinum-Sensitive, High-Grade Serous or Endometrioid Epithelial Ovarian, Primary Peritoneal or Fallopian Tube Cancer
Phase 3 Study of Rucaparib as Switch Maintenance After Platinum in Relapsed High Grade Serous and Endometrioid Ovarian Cancer (ARIEL3)
Status: Enrolling
Updated:  12/31/1969
Central Coast Medical Oncology
mi
from
Santa Maria, CA
A Study of Rucaparib as Switch Maintenance Following Platinum-Based Chemotherapy in Patients With Platinum-Sensitive, High-Grade Serous or Endometrioid Epithelial Ovarian, Primary Peritoneal or Fallopian Tube Cancer
Phase 3 Study of Rucaparib as Switch Maintenance After Platinum in Relapsed High Grade Serous and Endometrioid Ovarian Cancer (ARIEL3)
Status: Enrolling
Updated: 12/31/1969
Central Coast Medical Oncology
mi
from
Santa Maria, CA
Click here to add this to my saved trials
ASPREE Cancer Endpoints Study
ASPREE Cancer Endpoints Study
Status: Enrolling
Updated:  12/31/1969
Albert Einstein Medical Center
mi
from
Philadelphia, PA
ASPREE Cancer Endpoints Study
ASPREE Cancer Endpoints Study
Status: Enrolling
Updated: 12/31/1969
Albert Einstein Medical Center
mi
from
Philadelphia, PA
Click here to add this to my saved trials
ASPREE Cancer Endpoints Study
ASPREE Cancer Endpoints Study
Status: Enrolling
Updated:  12/31/1969
Baton Rouge General
mi
from
Baton Rouge, LA
ASPREE Cancer Endpoints Study
ASPREE Cancer Endpoints Study
Status: Enrolling
Updated: 12/31/1969
Baton Rouge General
mi
from
Baton Rouge, LA
Click here to add this to my saved trials
ASPREE Cancer Endpoints Study
ASPREE Cancer Endpoints Study
Status: Enrolling
Updated:  12/31/1969
Central Jersey Medical Center
mi
from
Elizabeth, NJ
ASPREE Cancer Endpoints Study
ASPREE Cancer Endpoints Study
Status: Enrolling
Updated: 12/31/1969
Central Jersey Medical Center
mi
from
Elizabeth, NJ
Click here to add this to my saved trials
ASPREE Cancer Endpoints Study
ASPREE Cancer Endpoints Study
Status: Enrolling
Updated:  12/31/1969
Detroit Clinical Research Center
mi
from
Novi, MI
ASPREE Cancer Endpoints Study
ASPREE Cancer Endpoints Study
Status: Enrolling
Updated: 12/31/1969
Detroit Clinical Research Center
mi
from
Novi, MI
Click here to add this to my saved trials
ASPREE Cancer Endpoints Study
ASPREE Cancer Endpoints Study
Status: Enrolling
Updated:  12/31/1969
Emory/ Atlanta VAMC
mi
from
Atlanta, GA
ASPREE Cancer Endpoints Study
ASPREE Cancer Endpoints Study
Status: Enrolling
Updated: 12/31/1969
Emory/ Atlanta VAMC
mi
from
Atlanta, GA
Click here to add this to my saved trials
ASPREE Cancer Endpoints Study
ASPREE Cancer Endpoints Study
Status: Enrolling
Updated:  12/31/1969
Georgia Health Sciences University
mi
from
Augusta, GA
ASPREE Cancer Endpoints Study
ASPREE Cancer Endpoints Study
Status: Enrolling
Updated: 12/31/1969
Georgia Health Sciences University
mi
from
Augusta, GA
Click here to add this to my saved trials
ASPREE Cancer Endpoints Study
ASPREE Cancer Endpoints Study
Status: Enrolling
Updated:  12/31/1969
Health Partners Research Foundation
mi
from
Minneapolis, MN
ASPREE Cancer Endpoints Study
ASPREE Cancer Endpoints Study
Status: Enrolling
Updated: 12/31/1969
Health Partners Research Foundation
mi
from
Minneapolis, MN
Click here to add this to my saved trials
ASPREE Cancer Endpoints Study
ASPREE Cancer Endpoints Study
Status: Enrolling
Updated:  12/31/1969
Kansas University Medical Center
mi
from
Kansas City, KA
ASPREE Cancer Endpoints Study
ASPREE Cancer Endpoints Study
Status: Enrolling
Updated: 12/31/1969
Kansas University Medical Center
mi
from
Kansas City, KA
Click here to add this to my saved trials
ASPREE Cancer Endpoints Study
ASPREE Cancer Endpoints Study
Status: Enrolling
Updated:  12/31/1969
LSU Health Sciences- New Orleans
mi
from
New Orleans, LA
ASPREE Cancer Endpoints Study
ASPREE Cancer Endpoints Study
Status: Enrolling
Updated: 12/31/1969
LSU Health Sciences- New Orleans
mi
from
New Orleans, LA
Click here to add this to my saved trials
ASPREE Cancer Endpoints Study
ASPREE Cancer Endpoints Study
Status: Enrolling
Updated:  12/31/1969
LSU Health Sciences- Shreveport
mi
from
Shreveport, LA
ASPREE Cancer Endpoints Study
ASPREE Cancer Endpoints Study
Status: Enrolling
Updated: 12/31/1969
LSU Health Sciences- Shreveport
mi
from
Shreveport, LA
Click here to add this to my saved trials
ASPREE Cancer Endpoints Study
ASPREE Cancer Endpoints Study
Status: Enrolling
Updated:  12/31/1969
Mary Bird Perkins Our Lady of the Lake Cancer Center
mi
from
Baton Rouge, LA
ASPREE Cancer Endpoints Study
ASPREE Cancer Endpoints Study
Status: Enrolling
Updated: 12/31/1969
Mary Bird Perkins Our Lady of the Lake Cancer Center
mi
from
Baton Rouge, LA
Click here to add this to my saved trials
ASPREE Cancer Endpoints Study
ASPREE Cancer Endpoints Study
Status: Enrolling
Updated:  12/31/1969
Mary Bird Perkins St. Tammany Parish Hospital
mi
from
Covington, LA
ASPREE Cancer Endpoints Study
ASPREE Cancer Endpoints Study
Status: Enrolling
Updated: 12/31/1969
Mary Bird Perkins St. Tammany Parish Hospital
mi
from
Covington, LA
Click here to add this to my saved trials
ASPREE Cancer Endpoints Study
ASPREE Cancer Endpoints Study
Status: Enrolling
Updated:  12/31/1969
Mary Bird Perkins Terrebonne General Hospital
mi
from
Houma, LA
ASPREE Cancer Endpoints Study
ASPREE Cancer Endpoints Study
Status: Enrolling
Updated: 12/31/1969
Mary Bird Perkins Terrebonne General Hospital
mi
from
Houma, LA
Click here to add this to my saved trials
ASPREE Cancer Endpoints Study
ASPREE Cancer Endpoints Study
Status: Enrolling
Updated:  12/31/1969
Meharry Medical College
mi
from
Nashville, TN
ASPREE Cancer Endpoints Study
ASPREE Cancer Endpoints Study
Status: Enrolling
Updated: 12/31/1969
Meharry Medical College
mi
from
Nashville, TN
Click here to add this to my saved trials
ASPREE Cancer Endpoints Study
ASPREE Cancer Endpoints Study
Status: Enrolling
Updated:  12/31/1969
Memorial Hospital of Rhode Island
mi
from
Pawtucket, RI
ASPREE Cancer Endpoints Study
ASPREE Cancer Endpoints Study
Status: Enrolling
Updated: 12/31/1969
Memorial Hospital of Rhode Island
mi
from
Pawtucket, RI
Click here to add this to my saved trials
ASPREE Cancer Endpoints Study
ASPREE Cancer Endpoints Study
Status: Enrolling
Updated:  12/31/1969
Morehouse School of Medicine
mi
from
Atlanta, GA
ASPREE Cancer Endpoints Study
ASPREE Cancer Endpoints Study
Status: Enrolling
Updated: 12/31/1969
Morehouse School of Medicine
mi
from
Atlanta, GA
Click here to add this to my saved trials
ASPREE Cancer Endpoints Study
ASPREE Cancer Endpoints Study
Status: Enrolling
Updated:  12/31/1969
New Jersey Medical College
mi
from
Newark, NJ
ASPREE Cancer Endpoints Study
ASPREE Cancer Endpoints Study
Status: Enrolling
Updated: 12/31/1969
New Jersey Medical College
mi
from
Newark, NJ
Click here to add this to my saved trials
ASPREE Cancer Endpoints Study
ASPREE Cancer Endpoints Study
Status: Enrolling
Updated:  12/31/1969
Palo Alto Medical Foundation Research Institute
mi
from
Palo Alto, CA
ASPREE Cancer Endpoints Study
ASPREE Cancer Endpoints Study
Status: Enrolling
Updated: 12/31/1969
Palo Alto Medical Foundation Research Institute
mi
from
Palo Alto, CA
Click here to add this to my saved trials
ASPREE Cancer Endpoints Study
ASPREE Cancer Endpoints Study
Status: Enrolling
Updated:  12/31/1969
Pennington Biomedical Research Center
mi
from
Baton Rouge, LA
ASPREE Cancer Endpoints Study
ASPREE Cancer Endpoints Study
Status: Enrolling
Updated: 12/31/1969
Pennington Biomedical Research Center
mi
from
Baton Rouge, LA
Click here to add this to my saved trials
ASPREE Cancer Endpoints Study
ASPREE Cancer Endpoints Study
Status: Enrolling
Updated:  12/31/1969
Queens Cancer Medical Center
mi
from
Queens, NY
ASPREE Cancer Endpoints Study
ASPREE Cancer Endpoints Study
Status: Enrolling
Updated: 12/31/1969
Queens Cancer Medical Center
mi
from
Queens, NY
Click here to add this to my saved trials
ASPREE Cancer Endpoints Study
ASPREE Cancer Endpoints Study
Status: Enrolling
Updated:  12/31/1969
Regional Academic Health Center
mi
from
Harlingen, TX
ASPREE Cancer Endpoints Study
ASPREE Cancer Endpoints Study
Status: Enrolling
Updated: 12/31/1969
Regional Academic Health Center
mi
from
Harlingen, TX
Click here to add this to my saved trials
ASPREE Cancer Endpoints Study
ASPREE Cancer Endpoints Study
Status: Enrolling
Updated:  12/31/1969
Rush Alzheimer's Disease Center
mi
from
Chicago, IL
ASPREE Cancer Endpoints Study
ASPREE Cancer Endpoints Study
Status: Enrolling
Updated: 12/31/1969
Rush Alzheimer's Disease Center
mi
from
Chicago, IL
Click here to add this to my saved trials
ASPREE Cancer Endpoints Study
ASPREE Cancer Endpoints Study
Status: Enrolling
Updated:  12/31/1969
SUNY Downstate Medical Center
mi
from
Brooklyn, NY
ASPREE Cancer Endpoints Study
ASPREE Cancer Endpoints Study
Status: Enrolling
Updated: 12/31/1969
SUNY Downstate Medical Center
mi
from
Brooklyn, NY
Click here to add this to my saved trials
ASPREE Cancer Endpoints Study
ASPREE Cancer Endpoints Study
Status: Enrolling
Updated:  12/31/1969
The Brody School of Medicine at ECU
mi
from
Greenville, NC
ASPREE Cancer Endpoints Study
ASPREE Cancer Endpoints Study
Status: Enrolling
Updated: 12/31/1969
The Brody School of Medicine at ECU
mi
from
Greenville, NC
Click here to add this to my saved trials
ASPREE Cancer Endpoints Study
ASPREE Cancer Endpoints Study
Status: Enrolling
Updated:  12/31/1969
University of Alabama at Birmingham
mi
from
Birmingham, AL
ASPREE Cancer Endpoints Study
ASPREE Cancer Endpoints Study
Status: Enrolling
Updated: 12/31/1969
University of Alabama at Birmingham
mi
from
Birmingham, AL
Click here to add this to my saved trials
ASPREE Cancer Endpoints Study
ASPREE Cancer Endpoints Study
Status: Enrolling
Updated:  12/31/1969
Tulane Medical Center
mi
from
New Orleans, LA
ASPREE Cancer Endpoints Study
ASPREE Cancer Endpoints Study
Status: Enrolling
Updated: 12/31/1969
Tulane Medical Center
mi
from
New Orleans, LA
Click here to add this to my saved trials
ASPREE Cancer Endpoints Study
ASPREE Cancer Endpoints Study
Status: Enrolling
Updated:  12/31/1969
University of Iowa
mi
from
Iowa City, IA
ASPREE Cancer Endpoints Study
ASPREE Cancer Endpoints Study
Status: Enrolling
Updated: 12/31/1969
University of Iowa
mi
from
Iowa City, IA
Click here to add this to my saved trials
ASPREE Cancer Endpoints Study
ASPREE Cancer Endpoints Study
Status: Enrolling
Updated:  12/31/1969
University of Michigan
mi
from
Ann Arbor, MI
ASPREE Cancer Endpoints Study
ASPREE Cancer Endpoints Study
Status: Enrolling
Updated: 12/31/1969
University of Michigan
mi
from
Ann Arbor, MI
Click here to add this to my saved trials
ASPREE Cancer Endpoints Study
ASPREE Cancer Endpoints Study
Status: Enrolling
Updated:  12/31/1969
University of Pittsburgh Health Sciences Research Center
mi
from
Pittsburgh, PA
ASPREE Cancer Endpoints Study
ASPREE Cancer Endpoints Study
Status: Enrolling
Updated: 12/31/1969
University of Pittsburgh Health Sciences Research Center
mi
from
Pittsburgh, PA
Click here to add this to my saved trials
ASPREE Cancer Endpoints Study
ASPREE Cancer Endpoints Study
Status: Enrolling
Updated:  12/31/1969
University of Tennessee Health Science Center
mi
from
Memphis, TN
ASPREE Cancer Endpoints Study
ASPREE Cancer Endpoints Study
Status: Enrolling
Updated: 12/31/1969
University of Tennessee Health Science Center
mi
from
Memphis, TN
Click here to add this to my saved trials
ASPREE Cancer Endpoints Study
ASPREE Cancer Endpoints Study
Status: Enrolling
Updated:  12/31/1969
UT Southwestern Medical Center
mi
from
Dallas, TX
ASPREE Cancer Endpoints Study
ASPREE Cancer Endpoints Study
Status: Enrolling
Updated: 12/31/1969
UT Southwestern Medical Center
mi
from
Dallas, TX
Click here to add this to my saved trials
ASPREE Cancer Endpoints Study
ASPREE Cancer Endpoints Study
Status: Enrolling
Updated:  12/31/1969
University of TX Medical Branch
mi
from
Galveston, TX
ASPREE Cancer Endpoints Study
ASPREE Cancer Endpoints Study
Status: Enrolling
Updated: 12/31/1969
University of TX Medical Branch
mi
from
Galveston, TX
Click here to add this to my saved trials
ASPREE Cancer Endpoints Study
ASPREE Cancer Endpoints Study
Status: Enrolling
Updated:  12/31/1969
UT Health Science Center - San Antonio
mi
from
San Antonio, TX
ASPREE Cancer Endpoints Study
ASPREE Cancer Endpoints Study
Status: Enrolling
Updated: 12/31/1969
UT Health Science Center - San Antonio
mi
from
San Antonio, TX
Click here to add this to my saved trials
ASPREE Cancer Endpoints Study
ASPREE Cancer Endpoints Study
Status: Enrolling
Updated:  12/31/1969
Wake Forest University Baptist Medical Center
mi
from
Greensboro, NC
ASPREE Cancer Endpoints Study
ASPREE Cancer Endpoints Study
Status: Enrolling
Updated: 12/31/1969
Wake Forest University Baptist Medical Center
mi
from
Greensboro, NC
Click here to add this to my saved trials
ASPREE Cancer Endpoints Study
ASPREE Cancer Endpoints Study
Status: Enrolling
Updated:  12/31/1969
Wayne State University
mi
from
Detroit, MI
ASPREE Cancer Endpoints Study
ASPREE Cancer Endpoints Study
Status: Enrolling
Updated: 12/31/1969
Wayne State University
mi
from
Detroit, MI
Click here to add this to my saved trials
ASPREE Cancer Endpoints Study
ASPREE Cancer Endpoints Study
Status: Enrolling
Updated:  12/31/1969
Winthrop University Hospital
mi
from
Mineola, NY
ASPREE Cancer Endpoints Study
ASPREE Cancer Endpoints Study
Status: Enrolling
Updated: 12/31/1969
Winthrop University Hospital
mi
from
Mineola, NY
Click here to add this to my saved trials
ASPREE Cancer Endpoints Study
ASPREE Cancer Endpoints Study
Status: Enrolling
Updated:  12/31/1969
Henry Ford Health System
mi
from
Detroit, MI
ASPREE Cancer Endpoints Study
ASPREE Cancer Endpoints Study
Status: Enrolling
Updated: 12/31/1969
Henry Ford Health System
mi
from
Detroit, MI
Click here to add this to my saved trials
ASPREE Cancer Endpoints Study
ASPREE Cancer Endpoints Study
Status: Enrolling
Updated:  12/31/1969
University of Florida Department of Aging and Geriatrics
mi
from
Gainesville, FL
ASPREE Cancer Endpoints Study
ASPREE Cancer Endpoints Study
Status: Enrolling
Updated: 12/31/1969
University of Florida Department of Aging and Geriatrics
mi
from
Gainesville, FL
Click here to add this to my saved trials